In HFrEF, carvedilol reduces mortality — that evidence is solid. In HFpEF, the same drug has been tested and the mortality benefit does not hold. The 2022 AHA/ACC/HFSA Heart Failure Guidelines do not recommend beta-blockers as a routine primary therapy for HFpEF. Management targets instead are the underlying drivers: hypertension, volume overload, and rate control if atrial fibrillation is present.
The common mistake
On an open-ended probe asking what to add to an HFpEF patient already on lisinopril, Jordan answered carvedilol — and gave a confident rationale. The reasoning: beta-blockers reduce fluid overload and control hypertension in heart failure patients, so they should help in HFpEF too.
It sounds reasonable. Beta-blockers are on every heart failure card. The problem is that the reasoning borrows an HFrEF framework and applies it somewhere it doesn't fit. A lot of Step 2 test-takers make this same call — not because they don't know the drugs, but because they know HFrEF so well that HFpEF starts to look like a smaller version of the same disease.
The tutor's correction identified two errors in that answer: beta-blockers don't diurese (that's furosemide), and carvedilol has no proven mortality benefit in HFpEF when there's no specific indication driving its use.
The actual mechanism
The tutor walked through this distinction directly:
In HFrEF, the ventricle is dilated and flabby. Blood fills it relatively passively. The problem is contractility — the heart fills but can't squeeze. ACE inhibitors and beta-blockers reduce neurohormonal activation (the renin-angiotensin-aldosterone system and sympathetic nervous system), which slows remodeling and improves survival. That's why ACEi + beta-blocker is the mortality-reducing backbone in HFrEF.
In HFpEF, the ventricle is stiff — it resists passive filling. The problem isn't pump failure; it's that the heart can't relax enough to fill properly. The neurohormonal remodeling cascade that beta-blockers target in HFrEF isn't the same mechanism driving HFpEF. Trials of beta-blockers in HFpEF populations have not demonstrated the same mortality reduction.
The tutor explained the treatment targets for HFpEF this way: control blood pressure, diurese for volume overload, and rate-control if atrial fibrillation is present (because the stiff ventricle depends on adequate filling time — tachycardia cuts that window short, and Afib eliminates atrial kick entirely — the same mechanism that makes Afib cardioversion timing so clinically consequential in these patients). No drug has demonstrated a clear mortality benefit in HFpEF as a class target.
This is the framework the tutor returned to across multiple sessions. In a follow-up open-ended question — "patient with HFpEF, normal sinus rhythm, well-controlled BP on lisinopril, euvolemic; what do you add for mortality benefit?" — the correct answer was: nothing. No drug has proven mortality benefit in HFpEF in that scenario.
Where a beta-blocker is appropriate in HFpEF: when there is a specific indication driving it, such as atrial fibrillation needing rate control, or uncontrolled hypertension. The drug choice then follows the indication, not a default HFpEF management protocol.
How to remember it
The frame that holds it: - HFrEF: weak pump → target neurohormonal remodeling → ACEi + beta-blocker = mortality benefit - HFpEF: stiff wall → target the drivers → control BP, volume, rate
No remodeling drugs. No mortality drugs by default. Treat what's making the ventricle worse.
A one-line anchor: In HFpEF, you treat the cause, not the pump.
Check yourself
A 67-year-old woman with HFpEF (EF 58%) is euvolemic, in normal sinus rhythm, and has well-controlled blood pressure on amlodipine. Which of the following would you add for long-term mortality benefit?
A) Carvedilol
B) Spironolactone
C) Sacubitril-valsartan
D) No additional drug has demonstrated mortality benefit in this scenario
Correct answer: D.
In a patient with HFpEF who has no uncontrolled hypertension, no atrial fibrillation, and is euvolemic, no drug class has demonstrated a proven mortality benefit in the way ACEi and beta-blockers have in HFrEF. The 2022 AHA/ACC/HFSA guidelines reflect this gap. SGLT2 inhibitors (empagliflozin, dapagliflozin) carry a Class 2a recommendation in HFpEF for reducing the composite of HF hospitalizations and cardiovascular mortality — but the trial signal was driven predominantly by the hospitalization component, not standalone mortality, and in this scenario (asymptomatic, euvolemic, well-controlled BP) the patient lacks a strong trigger for SGLT2i initiation. D remains the correct answer because no agent in this scenario has the HFrEF-style standalone mortality evidence.
Where to verify this
The 2022 AHA/ACC/HFSA Heart Failure Guidelines are the primary reference for this distinction. The guideline document is accessible via the American Heart Association. For a clinical summary, the StatPearls entry on Heart Failure with Preserved Ejection Fraction reviews current management evidence and the absence of proven mortality-reducing therapies comparable to HFrEF. The ACC's key takeaways from the 2022 guideline provides a concise summary of what changed for HFpEF, including the new SGLT2i evidence.
Close the gap
The tutor that caught Jordan's carvedilol answer — and traced it back to an HFrEF frame being applied where it doesn't belong — is the same tutor available to work through your specific gaps right now. If you just got a heart failure question wrong on a practice block, that's the right moment to drill it.